Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Naureen Adam

Interventional Pain Medicine Atlanta, GA Medical Doctor

NPI 1518174457 CMS profile 249727

2061 Peachtree Rd Ne, Ste 225, Atlanta, GA 30309

Open in the dashboard

General payments

$5,862

12 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naureen Adam of Atlanta, GA is reported in the CMS Open Payments database as having received $5,862 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20 1
2022 General $99 1
2020 General $49 3
2019 General $5,695 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naureen Adam
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Naureen Adam were reported at $20. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Naureen Adam Interventional Pain Medicine median Middle half National median
2019 $5,695 $684 $216–$2,079 $163
2020 $49 $382 $122–$1,109 $114
2021 $0 $552 $167–$1,554 $132
2022 $99 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $20 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Tosoh Bioscience, Inc. $5,210 2 payments
  2. Medtronic USA, Inc. $305 3 payments
  3. SI-BONE, Inc. $179 2 payments
  4. Stimwave Technologies Incorporated $99 1 payment
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $34 2 payments
  6. AbbVie, Inc. $20 1 payment
  7. Collegium Pharmaceutical, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Gift $5,210 2 payments
  2. Food and Beverage $652 10 payments
Products named General payments · program years 2019–2025
  1. TES, ST AIA-PACK $5,210 2 payments
  2. TES, AIA-PACK CALIBRATOR SET $5,210 2 payments
  3. PA, AIA-PACK Calibrator Set $2,605 1 payment
  4. ST AIA-PACK PROGIII CAL SET $2,605 1 payment
  5. FT3, AIA-PACK Calibrator Set $2,605 1 payment
  6. E2, ST Pack Calibrator Set $2,605 1 payment
  7. DHEA-S, ST AIA Pack Calibrator Set $2,605 1 payment
  8. FT4, AIA-PACK Calibrator Set $2,605 1 payment
  9. MYSTIM $207 2 payments
  10. IFUSE IMPLANT $179 2 payments
  11. Other $660 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

166

Median for Interventional Pain Management: 1,220

Drug cost

$2,846

Median for Interventional Pain Management: $39,344

Branded share of claims

10.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluconazole Generic 48 $1,351
Hydroxychloroquine Sulfate Generic 19 $508
Hydrocortisone Generic 18 $435
Valacyclovir Valacyclovir Hcl Brand 18 $206
Liothyronine Sodium Generic 12 $175
Atenolol Generic 19 $97
Trazodone Hcl Generic 20 $58
Lisinopril Generic 12 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record